Peptide Atlas · Peptide

Thymopentin (TP5)

In a double-blind trial in 100 patients with moderate to severe atopic dermatitis, six weeks of daily subcutaneous thymopentin reduced clinical severity, itching and redness more than placebo.

emerging

provisional
PubChem 451417
2 citations
0 discussions
0 followers
RKDVY
TP5
Timunox
thymopoietin (32-36)

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Thymopentin (TP5). Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Thymopentin reduced atopic dermatitis severity versus placebo (RCT, n=100)	emerging	pmid 2185294
Thymopentin improved hepatitis B vaccine response in hemodialysis non-responders (RCT, n=40)	emerging	pmid 3065661

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.